31-08-2022
Aker BioMarine’s Patent Portfolio is Strengthened in the United States
(August 31, 2022) The United States Patent Trial and Appeal Board (PTAB) has rejected a challenge against Aker BioMarine’s...
08-09-2022
Aker BioMarine strengthens QRILL™ Aqua sales team with new talent
(Oslo, September 6, 2022) Aker BioMarine is enhancing its QRILL™ Aqua sales organization after successfully recruiting two...
06-09-2022
Aker BioMarine, CSIRO and Swisse winners of the 2022 Nutra Ingredients Asia Award
(Tuesday, September 6th, 2022) Aker BioMarine, CSIRO and Swisse took home this year’s Nutrition Research Project prize at...
01-09-2022
First commercial agreement signed for Lysoveta
Oslo, 1 September 2022: Reference is made to the stock exchange release on 11 January 2021, with the announcement of the...
28-07-2022
Breakthrough study demonstrates positive effects of krill oil to improve osteoarthritis of the knee
Oslo, July, 27, 2022: A new study conducted by CSIRO, Australia’s national science agency, across three clinical trial sites...
14-07-2022
Aker BioMarine - second quarter 2022
14 July 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 73 million and Adjusted EBITDA...
30-06-2022
Aker BioMarine Supports Antarctic Ecosystem Research with USD 1 Million
(June 30th, 2022, Oslo) At the UN Ocean Conference in Lisbon this week, Aker BioMarine announced its commitment to support...
15-06-2022
Ocean 14 Capital invests in AION
Ocean 14 Capital Ltd., a private equity firm that invests in companies and technologies offering sustainable solutions for...
15-06-2022
Aker BioMarine secures FDA approval for QRILL Aqua in the United States
The US salmon farming industry can now benefit from the proven health and nutritional benefits of krill. As of June 10th,...
25-05-2022
QRILL Aqua strengthens team with two new executive hires
Oslo, May 25, 2022: Aker BioMarine is adding to its Animal Health and Nutrition Business Unit organizational chart after...